| Today's Big NewsNov 3, 2022 |
| By Heather Landi CVS and Walgreens tentatively agreed to pay a combined $10 billion to resolve lawsuits brought by states and local governments alleging the retailers mishandled prescriptions of opioid painkillers. |
|
|
|
By Zoey Becker Regeneron's Eylea has long been the crown jewel of the company. Although the med's market exclusivity reign is nearing an end, the top seller once again brought in record sales for the quarter. |
By Max Bayer With COVID vaccine uptake slated to become more seasonal, Moderna is touting new horizons to keep investors chomping. The phase 2 data from the company's personalized cancer vaccine, slated for the fourth quarter, are top of mind. |
By Andrea Park An overloaded and understaffed supply chain has led to shortage after shortage of crucial medical gear since the start of the COVID-19 pandemic. |
By Ben Adams Pfizer and GSK are already prepping for battle as the pair race into the new respiratory syncytial virus (RSV) market. This week, both companies moved closer to regulatory approvals, and they could each see the first-ever approvals for an RSV vaccine in 2023. |
By Gabrielle Masson Exelixis has made its third deal in three days, this time paying Catalent Biologics $30 million cash for licensing rights to three of its antibody-drug conjugate candidates. |
By Frank Diamond The proportion of survey respondents who cited barriers to obtaining healthcare that were not related to cost nearly doubled over approximately 20 years. |
By Gabrielle Masson The cat’s out of the bag: Regeneron is leaving two drugs behind, including an NGF inhibitor targeting chronic pain and a cat allergy therapy. |
By Conor Hale The company announced the expansion of its AI-powered drug discovery platforms from small molecule medicines to the construction of larger and more complex biologic therapies. |
By Fraiser Kansteiner Teva and GSK have been feuding over the common generic carve-out known as "skinny labeling" for years, with contentions centering on GSK's Coreg. GSK has the upper hand for now, and if the verdict stands, that's bad news for generics makers, one lawyer argued. |
By Annalee Armstrong Abeona Therapeutics has overcome an FDA clinical hold to show that its cell therapy can heal wounds in patients with a rare connective tissue disease, teeing up an FDA filing in the new year. |
By Paige Minemyer Cigna beat the Street on both profit and revenue for the third quarter, according to Zacks Investment Research. |
By Andrea Park As Tandem dips even further into the red, it has taken a hatchet to previous sales estimates. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about a possible national data privacy law and the holes that need to be plugged, particularly in a post-Roe v. Wade world. We also eavesdrop on a panel at the Digital Pharma East conference on opportunities to leverage digital health tools and social determinants data, to improve patients’ health. |
|
|---|
|
|
|
Tuesday, November 8, 2022 | 12:30pm ET / 9:30am PT As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
